|
1
|
Xian H, Xian Y, Liu L, Wang Y, He J and
Huang J: Expression of β-nerve growth factor and homeobox A10 in
experimental cryptorchidism treated with exogenous nerve growth
factor. Mol Med Rep. 11:2875–2881. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Guo R, Sherman-Baust C and Abdelmohsen K:
miRNA-based ovarian cancer diagnosis and therapySarkar F: microRNA
Targeted Cancer Therapy. Springer; Cham: pp. 115–127. 2014,
View Article : Google Scholar
|
|
3
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hornstein E, Mansfield JH, Yekta S, Hu JK,
Harfe BD, McManus MT, Baskerville S, Bartel DP and Tabin CJ: The
microRNA miR-196 acts upstream of Hoxb8 and Shh in limb
development. Nature. 438:671–674. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boehm M and Slack FJ: microRNA control of
lifespan and metabolism. Cell Cycle. 5:837–840. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tang W, Jiang Y, Mu X, Xu L, Cheng W and
Wang X: MiR-135a functions as a tumor suppressor in epithelial
ovarian cancer and regulates HOXA10 expression. Cell Signal.
26:1420–1426. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang F, Chang TH, Kao CJ and Huang RS:
High expression of miR-532-5p, a tumor suppressor, leads to better
prognosis in ovarian cancer both in vivo and in vitro. Mol Cancer
Ther. 15:1123–1131. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao H, Yu X, Ding Y, Zhao J, Wang G, Wu
X, Jiang J, Peng C, Guo GZ and Cui S: MiR-770-5p inhibits cisplatin
chemoresistance in human ovarian cancer by targeting ERCC2.
Oncotarget. 7:53254–53268. 2016.PubMed/NCBI
|
|
9
|
Zhao X, Zhou Y, Chen YU and Yu F: miR-494
inhibits ovarian cancer cell proliferation and promotes apoptosis
by targeting FGFR2. Oncol Lett. 11:4245–4251. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hu K and Liang M: Upregulated microRNA-224
promotes ovarian cancer cell proliferation by targeting KLLN. In
Vitro Cell Dev Biol Anim. 53:149–156. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xiaohong Z, Lichun F, Na X, Kejian Z,
Xiaolan X and Shaosheng W: MiR-203 promotes the growth and
migration of ovarian cancer cells by enhancing glycolytic pathway.
Tumour Biol. 37:14989–14997. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen S, Chen X, Xiu YL, Sun KX and Zhao Y:
MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial
carcinoma tumorigenesis and progression. Cancer Lett. 362:122–130.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zheng HB, Zheng XG and Liu BP: miRNA-101
inhibits ovarian cancer cells proliferation and invasion by
down-regulating expression of SOCS-2. Int J Clin Exp Med.
8:20263–20270. 2015.PubMed/NCBI
|
|
14
|
Zang W, Wang Y, Du Y, Xuan X, Wang T, Li
M, Ma Y, Li P, Chen X, Dong Z and Zhao G: Differential expression
profiling of microRNAs and their potential involvement in
esophageal squamous cell carcinoma. Tumor Biol. 35:3295–3304. 2014.
View Article : Google Scholar
|
|
15
|
Cheng W, Gao JP, Zhang ZG, Jing-Ping GE,
Feng XU and Wei ZF: Study on microRNAs in urothelial carcinoma(II
grade) of the bladder. J Med Postgrad. 23:48–52. 2010.
|
|
16
|
Chen J, Sun D, Chu H, Gong Z, Zhang C,
Gong B, Li Y, Li N and Jiang L: Screening of differential microRNA
expression in gastric signet ring cell carcinoma and gastric
adenocarcinoma and target gene prediction. Oncol Rep. 33:2963–2971.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hatanaka Y, De Velasco MA, Kura Y,
Yamamoto Y, Kodama M, Nozawa M, Shimizu N, Yoshimura K, Yoshikawa
K, Nishio K and Uemura H: Abstract 3629: HOXA10 expression profiles
in prostate cancer. Cancer Res. 72 8 Suppl:S36292012. View Article : Google Scholar
|
|
18
|
Thorsteinsdottir U, Sauvageau G, Hough MR,
Dragowska W, Lansdorp PM, Lawrence HJ, Largman C and Humphries RK:
Overexpression of HOXA10 in murine hematopoietic cells perturbs
both myeloid and lymphoid differentiation and leads to acute
myeloid leukemia. Mol Cell Biol. 17:495–505. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chu MC, Selam FB and Taylor HS: HOXA10
regulates p53 expression and matrigel invasion in human breast
cancer cells. Cancer Biol Ther. 3:568–572. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chen Y, Zhang J, Wang H, Zhao J, Xu C, Du
Y, Luo X, Zheng F, Liu R, Zhang H and Ma D: miRNA-135a promotes
breast cancer cell migration and invasion by targeting HOXA10. BMC
Cancer. 12:1112012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Carrera M, Bitu CC, de Oliveira CE,
Cervigne NK, Graner E, Manninen A, Salo T and Coletta RD: HOXA10
controls proliferation, migration and invasion in oral squamous
cell carcinoma. Int J Clin Exp Pathol. 8:3613–3623. 2015.PubMed/NCBI
|
|
22
|
Kim JW, Kim JY, Kim JE, Kim SK, Chung HT
and Park CK: HOXA10 is associated with temozolomide resistance
through regulation of the homologous recombinant DNA repair pathway
in glioblastoma cell lines. Genes Cancer. 5:165–174.
2014.PubMed/NCBI
|
|
23
|
Zhang L, Wan Y, Jiang Y, Ma J, Liu J, Tang
W, Wang X and Cheng W: Upregulation HOXA10 homeobox gene in
endometrial cancer: Role in cell cycle regulation. Med Oncol.
31:522014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jougla E: Survival of cancer patients in
Europe (EUROCARE study). Rev Epidemiol Sante Publique. 44:473–475.
1996.(In French). PubMed/NCBI
|
|
26
|
Coward JI, Middleton K and Murphy F: New
perspectives on targeted therapy in ovarian cancer. Int J Womens
Health. 7:189–203. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zaman MS, Maher DM, Khan S, Jaggi M and
Chauhan SC: Current status and implications of microRNAs in ovarian
cancer diagnosis and therapy. J Ovarian Res. 5:442012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Nikitina EG, Urazova LN and Stegny VN:
MicroRNAs and human cancer. Exp Oncol. 34:2–8. 2012.PubMed/NCBI
|
|
29
|
Kim TH, Song JY, Park H, Jeong JY, Kwon
AY, Heo JH, Kang H, Kim G and An HJ: miR-145, targeting
high-mobility group A2, is a powerful predictor of patient outcome
in ovarian carcinoma. Cancer Lett. 356:937–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Xu S, Fu GB, Tao Z, OuYang J, Kong F,
Jiang BH, Wan X and Chen K: MiR-497 decreases cisplatin resistance
in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget.
6:26457–26471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Guan Y, Yao H, Zheng Z, Qiu G and Sun K:
MiR-125b targets BCL3 and suppresses ovarian cancer proliferation.
Int J Cancer. 128:2274–2283. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee YS and Dutta A: MicroRNAs in cancer.
Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nygren MK, Tekle C, Ingebrigtsen VA,
Mäkelä R, Krohn M, Aure MR, Nunes-Xavier CE, Perälä M, Tramm T,
Alsner J, et al: Identifying microRNAs regulating B7-H3 in breast
cancer: The clinical impact of microRNA-29c. Br J Cancer.
110:2072–2080. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim JJ, Taylor HS, Lu Z, Ladhani O,
Hastings JM, Jackson KS, Wu Y, Guo SW and Fazleabas AT: Altered
expression of HOXA10 in endometriosis: Potential role in
decidualization. Mol Hum Reprod. 13:323–332. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kelly M, Daftary G and Taylor HS: An
autoregulatory element maintains HOXA10 expression in endometrial
epithelial cells. Am J Obstet Gynecol. 194:1100–1109. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Daftary GS, Troy PJ, Bagot CN, Young SL
and Taylor HS: Direct regulation of beta3-integrin subunit gene
expression by HOXA10 in endometrial cells. Mol Endocrinol.
16:571–579. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cheng W, Liu J, Yoshida H, Rosen D and
Naora H: Lineage infidelity of epithelial ovarian cancers is
controlled by HOX genes that specify regional identity in the
reproductive tract. Nat Med. 11:531–537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shih IeM, Chen L, Wang CC, Gu J, Davidson
B, Cope L, Kurman RJ, Xuan J and Wang TL: Distinct DNA methylation
profiles in ovarian serous neoplasms and their implications in
ovarian carcinogenesis. Am J Obstet Gynecol. 203(584): e1–22.
2010.
|
|
39
|
Pan BL, Tong ZW, Wu L, Pan L, Li JE, Huang
YG, Li SD, Du SX and Li XD: Effects of MicroRNA-206 on osteosarcoma
cell proliferation, apoptosis, migration and invasion by targeting
ANXA2 through the AKT signaling pathway. Cell Physiol Biochem.
45:1410–1422. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Libório-Kimura TN, Jung HM and Chan EK:
miR-494 represses HOXA10 expression and inhibits cell proliferation
in oral cancer. Oral Oncol. 51:151–157. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li B, Jin H, Yu Y, Gu C, Zhou X, Zhao N
and Feng Y: HOXA10 is overexpressed in human ovarian clear cell
adenocarcinoma and correlates with poor survival. Int J Gynecol
Cancer. 19:1347–1352. 2009. View Article : Google Scholar : PubMed/NCBI
|
